Pentosan polysulfate maculopathy: Prevalence, spectrum of disease, and choroidal imaging analysis based on prospective screening: Pentosan maculopathy: disease spectrum & choroidal analysis.

Abstract Purpose : To describe the prevalence and spectrum of disease of pentosan polysulfate (PPS) maculopathy in a large multimodal retinal imaging study and to report the results of choroidal vascularity index (CVI) analysis. Design : Prospective cohort study Methods : Of 741 patients prescribed PPS within a large university database, 100 (13.4%) with any consumption agreed to participate in a prospective screening investigation. Multimodal retinal imaging including near infrared reflectance (NIR), fundus autofluorescence (FAF), and spectral domain optical coherence tomography (SD-OCT) was performed in all patients. Characteristic findings of affected patients were identified and affected and unaffected cohorts were compared. CVI, defined as stromal choroidal area (SCA) divided by total choroidal area, was analyzed. Results : The prevalence of PPS maculopathy was 16%. NIR illustrated punctate hyperreflective lesions with early presentation. FAF illustrated a speckled macular network of hypo- and hyperautofluorescence colocalized with multifocal hyperreflective retinal pigment epithelial lesions on SD-OCT. Advanced cases demonstrated varying degrees of atrophy. The affected cohort exhibited significantly greater average PPS therapy duration, average daily dosage, and average cumulative dosage (19.5±5.5 years, 433.9±137.6 milligrams, 3103.1±1402.2 grams) compared to the unaffected cohort (7.1±6.6 years, 291.6±177.6 milligrams, 768.4±754.8 grams). SCA was significantly lower and CVI was significantly greater in the affected versus the unaffected group. Conclusions : This prospective cohort study identified a prevalence of PPS maculopathy of 15-20% among PPS users who agreed to participate. A spectrum of findings may be observed with multimodal retinal imaging. Significant choroidal abnormalities associated with this characteristic maculopathy may provide surrogate markers of macular toxicity.